buspirone has been researched along with Angelman Syndrome in 2 studies
Buspirone: An anxiolytic agent and serotonin receptor agonist belonging to the azaspirodecanedione class of compounds. Its structure is unrelated to those of the BENZODIAZAPINES, but it has an efficacy comparable to DIAZEPAM.
buspirone : An azaspiro compound that is 8-azaspiro[4.5]decane-7,9-dione substituted at the nitrogen atom by a 4-(piperazin-1-yl)butyl group which in turn is substituted by a pyrimidin-2-yl group at the N(4) position.
Angelman Syndrome: A syndrome characterized by multiple abnormalities, MENTAL RETARDATION, and movement disorders. Present usually are skull and other abnormalities, frequent infantile spasms (SPASMS, INFANTILE); easily provoked and prolonged paroxysms of laughter (hence happy); jerky puppetlike movements (hence puppet); continuous tongue protrusion; motor retardation; ATAXIA; MUSCLE HYPOTONIA; and a peculiar facies. It is associated with maternal deletions of chromosome 15q11-13 and other genetic abnormalities. (From Am J Med Genet 1998 Dec 4;80(4):385-90; Hum Mol Genet 1999 Jan;8(1):129-35)
| Excerpt | Relevance | Reference |
|---|---|---|
| "We describe three patients who were given open-label buspirone for the treatment of behaviors thought to be related to anxiety." | 7.91 | Buspirone for the treatment of anxiety-related symptoms in Angelman syndrome: a case series. ( Balaj, K; Keary, CJ; McDougle, CJ; Mullett, J; Nowinski, L; Palumbo, ML; Thibert, RL; Walsh, B, 2019) |
| "We describe three patients who were given open-label buspirone for the treatment of behaviors thought to be related to anxiety." | 3.91 | Buspirone for the treatment of anxiety-related symptoms in Angelman syndrome: a case series. ( Balaj, K; Keary, CJ; McDougle, CJ; Mullett, J; Nowinski, L; Palumbo, ML; Thibert, RL; Walsh, B, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tsagkaris, C | 1 |
| Papakosta, V | 1 |
| Miranda, AV | 1 |
| Zacharopoulou, L | 1 |
| Danilchenko, V | 1 |
| Matiashova, L | 1 |
| Dhar, A | 1 |
| Balaj, K | 1 |
| Nowinski, L | 1 |
| Walsh, B | 1 |
| Mullett, J | 1 |
| Palumbo, ML | 1 |
| Thibert, RL | 1 |
| McDougle, CJ | 1 |
| Keary, CJ | 1 |
1 review available for buspirone and Angelman Syndrome
| Article | Year |
|---|---|
Gene Therapy for Angelman Syndrome: Contemporary Approaches and Future Endeavors.
Topics: Angelman Syndrome; Animals; Anti-Anxiety Agents; Antiparkinson Agents; Buspirone; Diet, Ketogenic; D | 2020 |
1 other study available for buspirone and Angelman Syndrome
| Article | Year |
|---|---|
Buspirone for the treatment of anxiety-related symptoms in Angelman syndrome: a case series.
Topics: Adult; Angelman Syndrome; Anxiety; Anxiety Disorders; Buspirone; Female; Humans; Intellectual Disabi | 2019 |